CAPRICOR THERAPEUTICS, INC.CAPR
Market cap
$1.2B
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 320,648 | 326,904 | 164,732 | 41,896 | 110,865 | 125,719 | 144,174 | 157,652 | 171,956 | 143,890 | 245,697 | 533,131 | 1 | 1 |
| Stock-based compensation | 10 | 11 | 666,123 | 496,939 | 2 | 2 | 2 | 2 | 700,984 | 2 | 3 | 4 | 7 | 10 |
| Cash from operations | -4,649,292 | -2,186,681 | -6,144,001 | 958,562 | -10,817,286 | -15,801,620 | -14,230,879 | -13,862,441 | -6,821,501 | -10,054,810 | -16,809,324 | 5 | -25,596,545 | -39,995,742 |
| Capital expenditures | -130,855 | -130,855 | -284,923 | -186,431 | -129,697 | -191,970 | -32,185 | -316,486 | - | -547,601 | -1,196,286 | -2,000,243 | -1,311,660 | -1,166,871 |
| Cash from investing | -1,987 | - | - | 141,043 | -8,140,852 | -5,191,100 | 5 | 5 | -3,002,050 | 5 | -1,196,286 | -35,072,507 | 5 | -116,183,868 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | 193 | - | - | - | - | - |
| Proceeds from issuance of term debt, net | - | - | 4 | 5 | - | 5 | 500,000 | - | - | - | - | - | - | - |
| Cash from financing | 34 | 35 | - | 5 | 16 | 19 | 12 | 7 | 9 | 33 | 20 | 5 | 26 | 153 |
| Free cash flow | ||||||||||||||
| FCF margin (%) | - |